stuttering. Adult onset fluency disorder
Conditions
Interventions
Intervention 1: Intervention group: Resperidone 1 mg tablet of Sobhan company starts with a dose of 0.25 mg at night, then after a week it is increased to 1 mg at night. The duration of treatment is 6
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to 18 Years
Inclusion criteria
Inclusion criteria: Age range from 12 to 18 years Persian language Be literate in reading and writing Having a diagnosis of permanent developmental stuttering disorder based on the following criteria, the presence of both criteria is necessary: ??• Diagnosis of developmental stuttering by an experienced speech and language pathologist at the time of study • Obtaining a total score of 12 or higher in Riley's Stuttering Severity Test (SSI- 3) Absence of any language or speech disorder other than stuttering in the past or present (will be checked by self-reporting by each participant) Absence of any type of neurological, movement, vision, hearing, mental retardation, and autism spectrum disorders in the past or present, except for attention deficit hyperactivity disorder (ADHD) (with a clinical diagnosis by a psychiatrist) Not taking drugs affecting cognitive function before or during the research (self-reporting will be checked by each participant)
Exclusion criteria
Exclusion criteria: The person's unwillingness to cooperate in every stage of the research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - The primary outcome of the study includes the improvement of stuttering severity using the SSI-3 measurement tool and the SR score by the individual at the beginning of the study, two weeks and six weeks after the start of treatment during a visit to the clinic. Timepoint: At the beginning of the study, two weeks and six weeks after the start of the treatment, it is during a visit to the clinic. Method of measurement: The primary outcome of the study includes the improvement of stuttering severity using the SSI-3 measurement tool and the SR score by the individual at the beginning of the study, two weeks and six weeks after the start of treatment during a visit to the clinic. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Secondary outcome is determined by measuring the side effects of drug use based on the AIMS questionnaire by a psychiatric assistant in two weeks and six weeks after the start of treatment. Timepoint: in two weeks and six weeks after the start of treatment. Method of measurement: is determined by measuring the side effects of drug use based on the AIMS questionnaire by a psychiatric assistant. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Arman Masoudi
Babol University of Medical Sciences
Outcome results
None listed